These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17062694)

  • 41. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies.
    Kneissl S; Abel T; Rasbach A; Brynza J; Schneider-Schaulies J; Buchholz CJ
    PLoS One; 2012; 7(10):e46667. PubMed ID: 23071609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker.
    Peng KW; Donovan KA; Schneider U; Cattaneo R; Lust JA; Russell SJ
    Blood; 2003 Apr; 101(7):2557-62. PubMed ID: 12433686
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Retargeted and Stealth-Modified Oncolytic Measles Viruses for Systemic Cancer Therapy in Measles Immune Patients.
    Bah ES; Nace RA; Peng KW; Muñoz-Alía MÁ; Russell SJ
    Mol Cancer Ther; 2020 Oct; 19(10):2057-2067. PubMed ID: 32847970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Measles virus for cancer therapy.
    Russell SJ; Peng KW
    Curr Top Microbiol Immunol; 2009; 330():213-41. PubMed ID: 19203112
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Folate receptor specific anti-tumor activity of folate-mitomycin conjugates.
    Reddy JA; Westrick E; Vlahov I; Howard SJ; Santhapuram HK; Leamon CP
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):229-36. PubMed ID: 16331500
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus.
    Suksanpaisan L; Russell SJ; Peng KW
    Cancer Gene Ther; 2014 Jun; 21(6):256-60. PubMed ID: 24874841
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The contenders. Vaccines and viruses take aim at cancer cells.
    Clancy F
    Minn Med; 2005 Apr; 88(4):24-8. PubMed ID: 15940888
    [No Abstract]   [Full Text] [Related]  

  • 48. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunosuppression caused by measles virus: role of viral proteins.
    Kerdiles YM; Sellin CI; Druelle J; Horvat B
    Rev Med Virol; 2006; 16(1):49-63. PubMed ID: 16237742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Advances in measles virus for cancer therapy].
    Zhou D; Zhao ZY
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2015 Jul; 44(4):458-64. PubMed ID: 26555426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity.
    Allen C; Paraskevakou G; Iankov I; Giannini C; Schroeder M; Sarkaria J; Puri RK; Russell SJ; Galanis E
    Mol Ther; 2008 Sep; 16(9):1556-1564. PubMed ID: 28189011
    [TBL] [Abstract][Full Text] [Related]  

  • 52. MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors.
    Geekiyanage H; Galanis E
    Mol Oncol; 2016 Nov; 10(9):1387-1403. PubMed ID: 27507538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.
    Kleinlützum D; Hanauer JDS; Muik A; Hanschmann KM; Kays SK; Ayala-Breton C; Peng KW; Mühlebach MD; Abel T; Buchholz CJ
    Front Oncol; 2017; 7():127. PubMed ID: 28695108
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer.
    Mader EK; Butler G; Dowdy SC; Mariani A; Knutson KL; Federspiel MJ; Russell SJ; Galanis E; Dietz AB; Peng KW
    J Transl Med; 2013 Jan; 11():20. PubMed ID: 23347343
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells.
    Hummel HD; Kuntz G; Russell SJ; Nakamura T; Greiner A; Einsele H; Topp MS
    J Gen Virol; 2009 Mar; 90(Pt 3):693-701. PubMed ID: 19218216
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.
    Ayala Breton C; Wikan N; Abbuhl A; Smith DR; Russell SJ; Peng KW
    Mol Ther Oncolytics; 2015; 2():15012. PubMed ID: 27119107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antitumor Virotherapy by Attenuated Measles Virus (MV).
    Guillerme JB; Gregoire M; Tangy F; Fonteneau JF
    Biology (Basel); 2013 Mar; 2(2):587-602. PubMed ID: 24832799
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional folate receptor alpha is elevated in the blood of ovarian cancer patients.
    Basal E; Eghbali-Fatourechi GZ; Kalli KR; Hartmann LC; Goodman KM; Goode EL; Kamen BA; Low PS; Knutson KL
    PLoS One; 2009 Jul; 4(7):e6292. PubMed ID: 19617914
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity.
    Nosaki K; Hamada K; Takashima Y; Sagara M; Matsumura Y; Miyamoto S; Hijikata Y; Okazaki T; Nakanishi Y; Tani K
    Mol Ther Oncolytics; 2016; 3():16022. PubMed ID: 27847861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using Cystine Knot Proteins as a Novel Approach to Retarget Oncolytic Measles Virus.
    Lal S; Raffel C
    Mol Ther Oncolytics; 2017 Dec; 7():57-66. PubMed ID: 29367943
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.